Tuesday, November 7, 2017

Progenity Picks Up $125M For Genetic Testing Efforts

San Diego-based Progenity, a provider of genetic testing technology aimed at women's health, reproductive medicine, and oncology, has raised $125M in a Series B funding, the company said on Tuesday. The funding round was led by Athyrium Capital Management. According to Progenity, the funding will go to accelerate development of its gastrointestinal (GI) platform targeting diagnostics and therapeutics for the GI tract. The company is using that biotechnology for products in the areas of molecular diagnostics tools, precision therapeutics, microbiome analytics, and consumer health nutrition. Progenity's executive Chairman and founder is Harry Stylli. More information »